REHOVOT, Israel, and BRIDGEWATER, N.J., Oct. 27, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will announce third quarter ended September 30, 2015 financial results and host a conference call and webcast on Wednesday, November 11.
|Conference Call & Webcast|
|Wednesday, November 11th @ 8am Eastern Time|
|Replays, through November 25th|
About Foamix Pharmaceuticals Ltd.
Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing its proprietary minocycline foam for the treatment of acne and other skin conditions. Foamix Pharmaceuticals' lead product candidate FMX101 for moderate-to-severe acne is a novel topical foam formulation of the antibiotic minocycline. Foamix Pharmaceuticals also has early-stage stable foam formulations of various drugs for the treatment of common dermatological indications.
CONTACT: Ilan Hadar, CFO Foamix Pharmaceuticals Ltd. +972-8-9316233 email@example.com U.S. Investor Relations Michael Rice LifeSci Advisors, LLC 646-597-6979 firstname.lastname@example.org